Elevance Health Inc. (ELV) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Elevance Health Inc. (ELV) Tops Q2 EPS by 11c
July 18, 2024 6:13 AM EDT
RBC Capital analyst Ben Hendrix raised the price target on Elevance (NYSE: ELV) to $585.00 (from $575.00) while maintaining a Outperform rating.
The analyst comments "We believe ELV shares are oversold on known temporary Medicaid mix headwinds (which should ease over the next 612 months) and DCP optics... More
July 17, 2024 8:28 AM EDT
Morgan Stanley analyst Erin Wright reiterated an Overweight rating and $643.00 price target on Elevance (NYSE: ELV).
The analyst comments "Pre-Call View - ELV Shares Should Grind higher on Consolidated MLR Beat: While we await conf. call granularity on underlying cost trends by line of business, however, the... More
July 17, 2024 8:28 AM EDT
Truist Securities analyst David MacDonald reiterated a Buy rating and $620.00 price target on Elevance (NYSE: ELV).
The analyst comments "First Read Solid 2Q With MLR A Bit Better, Strong Growth At Carelon, FY Guidance Reaffirmed. ELV reported solid 2Q results featuring in-line revenues, MLR that was modestly better than our/consensus estimates and adjusted EPS also topped expectations with FY guidance of at least $37.20 reaffirmed. Operating revenue of $43.22B was roughly in-line with our $43.24BE and consensus $43.05B... More
